Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Batchelor

Showing results (261-270 of 321) with videos related to

Pageof 33
Sort By:
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Neurology|October 22, 2008
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group ReportS A Grimm, C A McCannel, A M P Omuro, et al.
Nature Reviews. Clinical Oncology|December 9, 2024
Leptomeningeal metastatic disease: new frontiers and future directionsAhmad Ozair, Hannah Wilding, Debarati Bhanja, et al.
Neuro-Oncology|April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastomaAndrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophagesTeresa E Peterson, Nathaniel D Kirkpatrick, Yuhui Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysisB Kasenda, A J M Ferreri, E Marturano, et al.
Neuro-Oncology|December 8, 2021
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-makingMary Jane Lim-Fat, Gilbert C Youssef, Mehdi Touat, et al.
Neuro-Oncology|February 9, 2021
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)Ramon F Barajas, Letterio S Politi, Nicoletta Anzalone, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Pageof 33

Showing results (261-270 of 321) with videos related to

Sort By:
Pageof 33
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Neurology|October 22, 2008
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group ReportS A Grimm, C A McCannel, A M P Omuro, et al.
Nature Reviews. Clinical Oncology|December 9, 2024
Leptomeningeal metastatic disease: new frontiers and future directionsAhmad Ozair, Hannah Wilding, Debarati Bhanja, et al.
Neuro-Oncology|April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastomaAndrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2016
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophagesTeresa E Peterson, Nathaniel D Kirkpatrick, Yuhui Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsBenjamin M Ellingson, Elizabeth R Gerstner, Marion Smits, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysisB Kasenda, A J M Ferreri, E Marturano, et al.
Neuro-Oncology|December 8, 2021
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-makingMary Jane Lim-Fat, Gilbert C Youssef, Mehdi Touat, et al.
Neuro-Oncology|February 9, 2021
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)Ramon F Barajas, Letterio S Politi, Nicoletta Anzalone, et al.
Cancer Cell|January 16, 2007
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor, A Gregory Sorensen, Emmanuelle di Tomaso, et al.
Pageof 33